Clinical trials: sponsored by Glaukos Corporation
Corneal Persistent Epithelial Defect
NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries
This study will enroll participants with a non-infected, corneal persistent epithelial defect (PED) resulting from an ocular chemical and/or thermal ocular injury which is non-responsive or refractory to current standard of care…
- Trial name
- EXPEDE (NCT04081103)
- Testing
- Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lufepirsen) Low Dose Concentration, Vehicle
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Glaukos Corporation
Glaucoma, Open-Angle, Ocular Hypertension
Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%
Phase III study to compare the safety and efficacy of intraocular implants containing travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, 0.5% (timolol) in reducing elevated intraocular pressure…
- Trial name
- NCT03519386
- Testing
- G2-TR intraocular implant containing travoprost
- Where
- United States
- Volunteers
- 590 people
- Sponsor
- Glaukos Corporation
Glaucoma, Open-Angle, Ocular Hypertension
Clinical Study Comparing Two Models of a Travoprost Intraocular Implant
Phase III study to compare the safety and efficacy of intraocular implants containing Travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, 0.5% (Timolol) in reducing elevated intraocular pressure…
- Trial name
- NCT03868124
- Testing
- G2-TR intraocular implant containing travoprost
- Where
- United States
- Volunteers
- 560 people
- Sponsor
- Glaukos Corporation
Glaucoma, Open-Angle, Ocular Hypertension
Performance of the Travoprost Intraocular Implant
To evaluate the performance of the Travoprost Intracameral Implant by determining residual drug in explanted implants of the Travoprost Intracameral Implant and by determining aqueous humor concentrations of travoprost free acid…
- Trial name
- NCT06582732
- Testing
- Travoprost Intracameral Implant exchanged at Month 12, Travoprost Intracameral Implant exchanged at Month 3, Travoprost Intracameral Implant exchanged at Month 6
- Where
- Armenia
- Volunteers
- 210 people
- Sponsor
- Glaukos Corporation
Progressive Keratoconus
Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus
To evaluate the safety and efficacy of epithelium-on corneal collagen cross-linking (CXL) in impeding the progression of, and/or reducing corneal curvature (Kmax) in eyes with progressive keratoconus.
- Trial name
- NCT03442751
- Testing
- Test Article A, Test Article B, KXL medical device system
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Glaukos Corporation
Open Angle Glaucoma
Study of Exchange of Travoprost Intraocular Implant
The study objective is to evaluate the safety of the operative and surgical exchange procedure of Travoprost Intraocular Implant in subjects with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT04615403
- Testing
- Travoprost
- Where
- 14 sites in United States, Philippines
- Volunteers
- 33 people
- Sponsor
- Glaukos Corporation
Glaucoma Open-angle
Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution
This is a randomized trial comparing two elution doses of the Travoprost Intraocular implant to timolol ophthalmic solution.
- Trial name
- NCT02754596
- Testing
- Travoprost Intraocular Implant, high elution, Travoprost Intraocular Implant, low elution, Timolol Maleate Ophthalmic Solution, 0.5%
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Glaukos Corporation
Ectasia
Corneal Collagen Cross-Linking for Ectasia (CXL)
Prospective, randomized multicenter study to determine the safety and effectiveness of performing corneal collagen cross-linking (CXL) using riboflavin and UVA light in eyes with ectasia after refractive surgery.
- Trial name
- CXL (NCT00674661)
- Testing
- riboflavin ophthalmic solution, UVA Irradiation
- Where
- 10 sites in United States
- Volunteers
- 130 people
- Sponsor
- Glaukos Corporation
Hyperopia, Hyperopic Astigmatism
Safety and Efficacy of Corneal Collagen Cross-linking Following LASIK for Treatment of Hyperopia and Hyperopic Astigmatism
The objectives of this study are to evaluate the safety and efficacy, with regards to regression of refractive outcome, as measured by manifest refraction spherical equivalent (MRSE), of two treatment regimens for hyperopic and…
- Trial name
- NCT01893359
- Testing
- riboflavin ophthalmic solution, 0% dextran, UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA), UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off)
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Glaukos Corporation
Progressive Keratoconus
Corneal Collagen Cross-linking for Progressive Keratoconus
Prospective, randomized multicenter study to determine the safety and effectiveness of performing cornea collagen cross-linking (CXL) using riboflavin and UVA light in eyes with progressive keratoconus.
- Trial name
- CXL (NCT00647699)
- Testing
- riboflavin ophthalmic solution, UVA Irradiation
- Where
- 10 sites in United States
- Volunteers
- 147 people
- Sponsor
- Glaukos Corporation
Open-Angle Glaucoma
A Study of the Trabecular Micro-bypass Stent in Combination With Cataract Surgery in Subjects With Open Angle Glaucoma
The purpose of this study is to evaluate the safety and efficacy of the iStent trabecular micro-bypass stent in reducing intraocular pressure (IOP) in subjects with open-angle glaucoma or ocular hypertension and co-existing…
- Trial name
- NCT00323284
- Testing
- iStent plus Cataract Surgery, Cataract surgery only
- Where
- 31 sites in United States
- Volunteers
- 240 people
- Sponsor
- Glaukos Corporation
Primary Open Angle Glaucoma
Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent: Extended Follow-up of the Premarket Cohort
The purpose of this study is to assess the long-term safety of the Glaukos® iStent® Trabecular Micro-Bypass Stent Model GTS100R/L in subjects previously enrolled in Glaukos Study GC-003.
- Trial name
- NCT01836042
- Where
- 26 sites in United States
- Volunteers
- 108 people
- Sponsor
- Glaukos Corporation
Open-angle Glaucoma
Safety and Efficacy of the GTS400 Stent in Conjunction With Cataract
To evaluate the safety and efficacy of the Glaukos Trabecular Micro-Bypass Stent Model GTS400 in conjunction with cataract surgery, compared to cataract surgery only, in subjects with mild to moderate open angle glaucoma.
- Trial name
- NCT00721968
- Testing
- Glaucoma Stent Surgery (GTS400 Stent), cataract surgery alone
- Volunteers
- 62 people
- Sponsor
- Glaukos Corporation